Literature DB >> 19533454

Outcome from surgery for vestibular schwannomas in children.

Stephen P MacNally1, Scott A Rutherford, Andrew T King, Simon Freeman, John Thorne, Deborah Mawman, Martin P O'Driscoll, D G Evans, Richard T Ramsden.   

Abstract

OBJECT: A review of sporadic and NF2-related vestibular schwannoma surgery in children (under 18 years of age) with a specific interest in resection rates, recurrence, facial nerve outcomes, hearing preservation, hearing rehabilitation and genetic analysis.
METHODS: A retrospective analysis of prospectively collected data of 35 consecutively operated vestibular schwannomas in 29 paediatric patients that underwent 38 operations between 1992 and 2007. Pre- and post-operative radiology, facial nerve function, pure tone audiogram and speech discrimination tests were performed with a mean follow-up of 4.5 years. Tumour and blood mutations were analysed in 86% of patients.
RESULTS: Total resection was achieved in all sporadic cases and 68% of NF2 cases. Near total resection led to tumour recurrence in 5 out of 10 cases. The facial nerve was anatomically preserved in 92%. Facial nerve function was excellent to good (Grades 1-3) in 88% with outcome related to tumour size. Hearing preservation was successful in 3 of 11 cases.
CONCLUSIONS: Surgery with complete resection results in excellent tumour control, but it is more difficult to attain total resection in NF2 with a relatively high recurrence rate of persistently growing tumours. A better facial outcome is associated with smaller tumours, near-total resection and first time surgery. Hearing preservation is possible in a minority. Hearing rehabilitation can be successful by utilising cochlear implants and auditory brain stem implants (ABI) as appropriate. Overall there is a low complication rate and results are comparable with adult series.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533454     DOI: 10.1080/02688690902968844

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  6 in total

1.  Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.

Authors:  Nicolas -Xavier Bonne; Rabih Aboukais; Marc Baroncini; Audrey Hochart; Pierre Leblond; Franck Broly; Frédérique Dubrulle; Jean-Paul Lejeune; Christophe Vincent
Journal:  Childs Nerv Syst       Date:  2016-10-04       Impact factor: 1.475

2.  Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation.

Authors:  Fu Zhao; Bo Wang; Zhijun Yang; Qiangyi Zhou; Peng Li; Xingchao Wang; Jing Zhang; Junting Zhang; Pinan Liu
Journal:  J Neurooncol       Date:  2018-02-28       Impact factor: 4.130

3.  Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2.

Authors:  Shi-Wei Li; Jing Zhang; Han-Lu Tang; Peng Li; Bo Wang; Fu Zhao; Pi-Nan Liu
Journal:  J Neurooncol       Date:  2021-11-09       Impact factor: 4.130

4.  Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges.

Authors:  Byung Sup Kim; Ho Jun Seol; Jung-Il Lee; Hyung Jin Shin; Kwan Park; Doo-Sik Kong; Do-Hyun Nam; Yang-Sun Cho
Journal:  Neurosurg Rev       Date:  2016-05-04       Impact factor: 3.042

5.  Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.

Authors:  Claire Forde; Andrew T King; Scott A Rutherford; Charlotte Hammerbeck-Ward; Simon K Lloyd; Simon R Freeman; Omar N Pathmanaban; Emma Stapleton; Owen M Thomas; Roger D Laitt; Stavros Stivaros; John-Paul Kilday; Grace Vassallo; Catherine McBain; Simon Kerrigan; Miriam J Smith; Martin G McCabe; Elaine F Harkness; D Gareth Evans
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

6.  Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.

Authors:  Stavros M Stivaros; Anat O Stemmer-Rachamimov; Robert Alston; Scott R Plotkin; Joseph B Nadol; Alicia Quesnel; Jennifer O'Malley; Gillian A Whitfield; Martin G McCabe; Simon R Freeman; Simon K Lloyd; Neville B Wright; John-Paul Kilday; Ian D Kamaly-Asl; Samantha J Mills; Scott A Rutherford; Andrew T King; D Gareth Evans
Journal:  J Med Genet       Date:  2015-06-23       Impact factor: 6.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.